Statistics for Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Total visits

views
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial 1

Total visits per month

views
August 2024 0
September 2024 0
October 2024 0
November 2024 0
December 2024 0
January 2025 0
February 2025 1